Danuglipron – an innovate GLP agonist - literature short review
DOI:
https://doi.org/10.12775/QS.2024.19.53802Keywords
danuglipron, weight loss, obesity, diabetes, GLP agonistAbstract
Obesity and type 2 diabetes mellitus (T2DM) are global health problems with increasing prevalence, associated with numerous metabolic, cardiovascular and renal complications(1,2). Current treatments include GLP-1 receptor agonists (GLP-1RAs), which have shown benefits in weight reduction and glycaemic control. Danuglipron, a novel, oral, small-molecule GLP-1RA, is being investigated for its efficacy in treating these conditions. The novel oral method of administration may contribute to an increase in its regularity of use among patients who find systematic use of injections difficult. The aim of our study is to describe this new drug, its' mechanism of action and discuss possible benefits versus adverse effects.
Obesity and type 2 diabetes mellitus (T2DM) represent significant global health challenges with a rising prevalence, linked to a multitude of metabolic, cardiovascular, and renal complications. Current therapeutic approaches encompass GLP-1 receptor agonists (GLP-1RAs), which have exhibited favorable outcomes in weight management and glycemic regulation. Danuglipron, an innovative oral small-molecule GLP-1RA, is undergoing investigation for its effectiveness in addressing these conditions. The unique oral delivery method could potentially enhance its adherence among patients encountering difficulties with routine injections. Our study aims to delineate this novel medication, elucidate its mechanism of action, and deliberate on the prospective benefits versus drawbacks.
References
Tomic D, The burden and risks of emerging complications of diabetes mellitus. 2022 doi:10.1038/s41574-022-00690-7
World Health Organization. Accelerating action to stop obesity, 2023.
World Health Organisation. Diabetes; 2023.
Saxena AR, Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial. 2023 doi:10.1038/s41591-021-01391-w
Congdon P, The obesity epidemic: Causes, context, prevention. 2022 doi: 10.3389/fpubh.2022.1030180
Jacqueline A. Seiglie, Diabetes Prevalence and Its Relationship With Education, Wealth, and BMI in 29 Low- and Middle-Income Countries. 2020 doi: 10.2337/dc19-1782
Hecker, J., Burden of disease study of overweight and obesity; the societal impact in terms of cost-of- illness and health-related quality of life. 2022 doi: https://doi.org/10.1186/s12889-021-12449-2
Griffith DA, A small-molecule oral ago-nist of the human glucagon-like peptide-1 receptor. 2022 doi: https://doi.org/10.1021/acs.jmedchem.1c01856
Gary E. Aspnes, 6-Azaspiro[2.5]acetates as small molecule agonists of the human glucagon- like peptide-1 receptor doi: https://doi.org/10.1016/j.bmcl.2023.129454
W. Timothy Garvey, American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity doi: https://doi.org/10.4158/EP161365.GL
Søren L Kristensen, Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials, 2019, DOI: 10.1016/S2213-8587(19)30249-9
Igarashi A, Preference for oral andinjectable GLP-1 RA therapy profiles in Japanese patients with type 2diabetes: a discrete choice experiment. 2021, DOI: 10.1007/s12325-020-01561-1
M.V. Sikirica Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross- sectional survey of physicians and their patients with type 2 diabetes, 2017, doi:10.2147/DMSO.S141235
Saxena AR, Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial. 2023 doi:10.1001/jamanetworkopen.2023.14493
Bækdal TA, Effect of various dosing conditions on the pharmacokinetics of oral semaglutide, a human glucagon-like peptide-1 analogue in a tablet formulation. 2021, doi:10.1007/s13300-021- 01078
Ono R, A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitus. Diabetes Obes Metab. 2023 doi: 10.1111/dom.14928.
Fatima H, Evaluating Glycemic Control Efficacy and Safety of the Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron in Type 2 Diabetes Patients: A Systemic Review and Meta- Analysis. 2023 Nov, doi: 10.2147/DMSO.S439587.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Agata Frańczuk, Angelika Szpulak, Ewelina Kopczyńska, Aleksandra Makłowicz, Katarzyna Kuleta, Julia Głoskowska, Michalina Grzelka, Katarzyna Słychan, Agnieszka Głuszczyk, Jakub Plizga
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 131
Number of citations: 0
